A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
about
Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomasClinical use and applications of histone deacetylase inhibitors in multiple myelomaPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Trials with 'epigenetic' drugs: an updateNew drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Clinical Toxicities of Histone Deacetylase Inhibitors.Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.The DAC system and associations with multiple myeloma.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Interpreting clinical assays for histone deacetylase inhibitors.Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancerTargeting inflammation in heart failure with histone deacetylase inhibitors.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Histone deacetylase inhibitors: clinical implications for hematological malignancies.ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis.L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors.An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.Development of target-specific treatments in multiple myeloma.Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.Small-molecule chromatin-modifying agents: therapeutic applications.Promises and challenges of anticancer drugs that target the epigenome.Panobinostat for the treatment of multiple myeloma.Toxicological and metabolic considerations for histone deacetylase inhibitors.The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.Future agents and treatment directions in multiple myeloma.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Keeping up the balance: role of HDACs in cardiac proteostasis and therapeutic implications for atrial fibrillation.Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.HDACs and HDAC Inhibitors in Cancer Development and Therapy.Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaEmerging drugs and combinations to treat multiple myeloma.
P2860
Q24310863-FF052B8A-931C-469F-BFA7-4337C3D74298Q26745930-C60C947E-0BF9-431D-9739-9FBEE061BA96Q26771601-74794CB9-69B0-438F-93F9-D31BE739DB64Q27000542-AAF85E19-AA80-4F71-A7A3-FA83C9AFD9BEQ27004421-22E5705E-58C4-46E0-9251-6629683F251AQ31135325-D860BF5B-F947-4A38-BA05-B46BD2FBF3F6Q33390876-7892BCA2-497B-4562-8185-BC570FBB0345Q33409340-3CB92BFA-B5DD-4CBD-94DD-09F8BAE05524Q33410997-8B6A2958-16F7-41CC-900A-855BECAECACFQ34224278-081E1694-65D7-4C24-8467-46AB78F04A20Q34414447-8CA047EF-2CDA-4838-BABF-72575C1E5E31Q34488424-46BC229C-4CE2-488D-B03E-1BC5F1FB664CQ35003657-059131A2-272A-420A-9C54-644302EE1A1AQ35016934-EA514F00-020A-4FCD-84FE-BC2A60D310CFQ35016989-3D05F323-ACF8-4249-88A0-8424B393A124Q35214924-765E7B6B-FA17-42E1-8D85-3931E1CC40BEQ36001847-5E7EF003-B620-41E8-AEE9-37E0053389B0Q36569602-9051D58D-405E-45DB-BA46-68F942129B13Q36712802-2D5EA2E3-50EF-4299-8B20-69F7E8DA8B17Q36751751-1B8A6035-23CF-4FD6-991B-676A95F0CE9BQ37310619-70A6977F-FFD4-4450-B7AF-AC80AC9A5051Q37503780-65AC2D7F-C5BE-4715-901E-AD6A7F16E46DQ37771370-711E5CB2-9A47-45F2-BB02-3F461DD96DC6Q37959304-1FBC20ED-C1E8-418B-B060-F371F2420F38Q37961728-A3919895-8CAF-4D59-9C85-C10E84EE8F05Q37962596-A50DC6F8-1345-467B-8F85-58B6E77E976BQ37992104-1B635344-2075-445F-8650-F188A0C50062Q38071321-BB4327D0-36C2-4E00-8A0A-F5A164678DDFQ38101381-D3034270-DBD7-44A5-83AC-97AFBC136157Q38161731-87B4142D-1AB2-4B04-BCA2-8FF396282EC2Q38172300-E5458A6C-76EE-41FD-8959-943EA13AE783Q38572855-15C15532-3E7F-49B9-83E1-E9920CDAF660Q38630472-1178B25A-DEDD-4437-BF9E-7577C6336A05Q38662343-12BC52FF-D28D-4975-A2A5-17803FE7D089Q38819408-60AE45B0-1193-4724-8A7C-07210F599938Q38947405-5CB5AAC8-2DD2-427B-A5DD-4954001F00BBQ39185574-9B766CC5-FBB5-4B81-B1B0-04441EB6F2BEQ39632688-D5E63A76-7979-4386-A63B-E75168A55EA9Q39768627-1E73E068-DDF0-48A8-B697-40F17A5A7330Q41694198-542F160D-B541-4234-AE5B-5E6CF97CEF49
P2860
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A phase II multiple dose clini ...... progressive multiple myeloma.
@ast
A phase II multiple dose clini ...... progressive multiple myeloma.
@en
type
label
A phase II multiple dose clini ...... progressive multiple myeloma.
@ast
A phase II multiple dose clini ...... progressive multiple myeloma.
@en
prefLabel
A phase II multiple dose clini ...... progressive multiple myeloma.
@ast
A phase II multiple dose clini ...... progressive multiple myeloma.
@en
P2093
P1433
P1476
A phase II multiple dose clini ...... progressive multiple myeloma.
@en
P2093
Alessandro Rambaldi
Antonella Gozzini
Claudia Crippa
Monica Galli
Norbert Pescosta
Silvia Salmoiraghi
P304
P356
10.1007/S00277-009-0793-8
P50
P577
2009-07-25T00:00:00Z